2bst
From Proteopedia
(New page: 200px<br /> <applet load="2bst" size="450" color="white" frame="true" align="right" spinBox="true" caption="2bst, resolution 2.1Å" /> '''CRYSTAL STRUCTURES A...) |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
We have solved the crystal structures of three HLA-B*2705-peptide, complexes with the immunodominant viral peptides: EBV EBNA3C 258-266, (RRIYDLIEL), influenza (flu) nucleoprotein NP383-391 (SRYWAIRTR), and HIV, gag 264-273 (KRWIILGLNK). Long-term non-progression during HIV infection, has been associated with presentation by HLA-B*2705, and T cell, recognition, of the highly immunodominant KRWIILGLNK peptide. The tight, hydrogen-bonding network observed between the HLA-B*2705 B-pocket and the, peptide P2 arginine guanadinium anchor explains why mutation of this, residue during HIV infection results in loss of peptide binding, immune, escape and progression to AIDS. Prominent, solvent-exposed structures, within these peptides may participate in generating T cell responses to, these immunodominant epitopes. In the HLA-B*2705 complex with flu, NP383-391, the amino acid side chains of residues 4, 7 and 8 are, solvent-exposed whilst in the HIV decamer, the main-chain bulges into the, solvent around P7. Thus, HLA-B*2705 presents viral peptides in a range of, conformations. Tetrameric complexes of HLA-B*2705 with the HIV and flu but, not EBV peptides bound strongly to the killer-Ig-like receptor (KIR)3DL1., Substitution of EBV P8 glutamate to threonine allowed recognition by, KIR3DL1. In the HLA-B*2705-EBV structure the P8 glutamate side chain is, solvent-exposed and may inhibit KIR3DL1 binding through electrostatic, forces. | We have solved the crystal structures of three HLA-B*2705-peptide, complexes with the immunodominant viral peptides: EBV EBNA3C 258-266, (RRIYDLIEL), influenza (flu) nucleoprotein NP383-391 (SRYWAIRTR), and HIV, gag 264-273 (KRWIILGLNK). Long-term non-progression during HIV infection, has been associated with presentation by HLA-B*2705, and T cell, recognition, of the highly immunodominant KRWIILGLNK peptide. The tight, hydrogen-bonding network observed between the HLA-B*2705 B-pocket and the, peptide P2 arginine guanadinium anchor explains why mutation of this, residue during HIV infection results in loss of peptide binding, immune, escape and progression to AIDS. Prominent, solvent-exposed structures, within these peptides may participate in generating T cell responses to, these immunodominant epitopes. In the HLA-B*2705 complex with flu, NP383-391, the amino acid side chains of residues 4, 7 and 8 are, solvent-exposed whilst in the HIV decamer, the main-chain bulges into the, solvent around P7. Thus, HLA-B*2705 presents viral peptides in a range of, conformations. Tetrameric complexes of HLA-B*2705 with the HIV and flu but, not EBV peptides bound strongly to the killer-Ig-like receptor (KIR)3DL1., Substitution of EBV P8 glutamate to threonine allowed recognition by, KIR3DL1. In the HLA-B*2705-EBV structure the P8 glutamate side chain is, solvent-exposed and may inhibit KIR3DL1 binding through electrostatic, forces. | ||
| + | |||
| + | ==Disease== | ||
| + | Known diseases associated with this structure: Abacavir hypersensitivity, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142830 142830]], Hypoproteinemia, hypercatabolic OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109700 109700]], Spondyloarthropathy, susceptibility to, 1 OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142830 142830]], Stevens-Johnson syndrome, carbamazepine-induced, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142830 142830]] | ||
==About this Structure== | ==About this Structure== | ||
| Line 34: | Line 37: | ||
[[Category: viral nucleoprotein]] | [[Category: viral nucleoprotein]] | ||
| - | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:05:59 2007'' |
Revision as of 18:59, 12 November 2007
|
CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
Contents |
Overview
We have solved the crystal structures of three HLA-B*2705-peptide, complexes with the immunodominant viral peptides: EBV EBNA3C 258-266, (RRIYDLIEL), influenza (flu) nucleoprotein NP383-391 (SRYWAIRTR), and HIV, gag 264-273 (KRWIILGLNK). Long-term non-progression during HIV infection, has been associated with presentation by HLA-B*2705, and T cell, recognition, of the highly immunodominant KRWIILGLNK peptide. The tight, hydrogen-bonding network observed between the HLA-B*2705 B-pocket and the, peptide P2 arginine guanadinium anchor explains why mutation of this, residue during HIV infection results in loss of peptide binding, immune, escape and progression to AIDS. Prominent, solvent-exposed structures, within these peptides may participate in generating T cell responses to, these immunodominant epitopes. In the HLA-B*2705 complex with flu, NP383-391, the amino acid side chains of residues 4, 7 and 8 are, solvent-exposed whilst in the HIV decamer, the main-chain bulges into the, solvent around P7. Thus, HLA-B*2705 presents viral peptides in a range of, conformations. Tetrameric complexes of HLA-B*2705 with the HIV and flu but, not EBV peptides bound strongly to the killer-Ig-like receptor (KIR)3DL1., Substitution of EBV P8 glutamate to threonine allowed recognition by, KIR3DL1. In the HLA-B*2705-EBV structure the P8 glutamate side chain is, solvent-exposed and may inhibit KIR3DL1 binding through electrostatic, forces.
Disease
Known diseases associated with this structure: Abacavir hypersensitivity, susceptibility to OMIM:[142830], Hypoproteinemia, hypercatabolic OMIM:[109700], Spondyloarthropathy, susceptibility to, 1 OMIM:[142830], Stevens-Johnson syndrome, carbamazepine-induced, susceptibility to OMIM:[142830]
About this Structure
2BST is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705., Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P, Eur J Immunol. 2005 Feb;35(2):341-51. PMID:15657948
Page seeded by OCA on Mon Nov 12 21:05:59 2007
Categories: Homo sapiens | Protein complex | Bowness, P. | Gleria, K.Di. | Jones, E.Y. | Kollnberger, S. | Mcmichael, A.J. | Stewart-Jones, G.B.E. | Complex (antigen/peptide) | Flu | Glycoprotein | Hiv | Hla-b27 | Human ebv | Immunoglobulin domain | Mhc | Mhc i | Polymorphism | Pyrrolidone carboxylic acid | Transmembrane | Viral nucleoprotein
